• Publications
  • Influence
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
A small proportion of patients with deep vein thrombosis develop recurrent venous thromboembolic complications or bleeding during anticoagulant treatment. These complications may occur moreExpand
  • 1,375
  • 47
  • PDF
Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.
BACKGROUND Little is known about the clinical, diagnostic, and prognostic aspects of upper-extremity deep vein thrombosis (UEDVT). OBJECTIVES To identify the clinical and laboratory parametersExpand
  • 485
  • 27
  • PDF
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626
BACKGROUND AND OBJECTIVES While it has long been recognized that patients with acute unprovoked deep vein thrombosis (DVT) or pulmonary embolism (PE) have a higher risk of recurrent venousExpand
  • 650
  • 22
  • PDF
The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.
BACKGROUND AND OBJECTIVE In contrast to the extensive documentation on the short-term outcome of patients with acute deep vein thrombosis (DVT) of the lower extremities, little is known about theExpand
  • 330
  • 12
  • PDF
Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis
There is no established management algorithm for portal vein thrombosis (PVT) in cirrhotic patients. The aim of our study was to prospectively evaluate anticoagulation and transjugular intrahepaticExpand
  • 233
  • 12
X-linked thrombophilia with a mutant factor IX (factor IX Padua).
We report a case of juvenile thrombophilia associated with a substitution of leucine for arginine at position 338 (R338L) in the factor IX gene (factor IX-R338L). The level of the mutant factor IXExpand
  • 208
  • 12
Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
Context Doctors typically treat deep venous thrombosis with anticoagulants for 3 to 6 months to prevent recurrence. Patients at high risk for recurrence may benefit from longer treatment. Can weExpand
  • 482
  • 11
Impact of Inherited Thrombophilia on Venous Thromboembolism in Children: A Systematic Review and Meta-Analysis of Observational Studies
Background— The aim of the present study was to estimate the impact of inherited thrombophilia (IT) on the risk of venous thromboembolism (VTE) onset and recurrence in children by a meta-analysis ofExpand
  • 208
  • 10
  • PDF
COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure
In late December 2019 an outbreak of a novel coronavirus (SARS-CoV-2) causing severe pneumonia (COVID-19) was reported in Wuhan, Hubei Province, China. A common finding in most COVID-19 patients isExpand
  • 203
  • 10
  • PDF
Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies
Background— The aim of this study was to estimate the impact of thrombophilia on risk of first childhood stroke through a meta-analysis of published observational studies. Methods and Results— AExpand
  • 305
  • 7